Navigation Links
Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/18/2007

CAMBRIDGE, England, October 18 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on two of its drug candidates, AT7519 and AT13148, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held October 22-26, 2007 in San Francisco.

AT7519 is a potent and selective Cyclin Dependent Kinase (CDK) inhibitor currently in multi-centre Phase 1 clinical trials. AT13148 is a potent and selective inhibitor of AKT and certain other AGC kinases, which is in pre-clinical development.

AT7519 and AT13148 are among five compounds currently being developed by Astex for the treatment of solid tumours and haematological malignancies. All of the compounds were discovered by Astex using its proprietary fragment-based drug discovery platform Pyramid(TM).

"With fewer than 100 people engaged in drug discovery and development at Astex, we have generated a development pipeline of five novel products in less than five years and put two of those products into clinical trials," said Leon Bushara, Chief Executive of Astex. "That record of productivity is a testament to the power of our drug discovery technology, the strength and focus of our organisation, and the ingenuity of our scientists. Going forward, we expect to introduce at least one new product into development every year."

In addition to AT7519 and AT13148, Astex is developing:

- AT9283, a multi-targeted inhibitor of Aurora kinases, JAK2 and BCR-Abl, currently in multiple Phase 1 and Phase 1/2 multi-center clinical trials;

- AT13387, a selective inhibitor of Hsp90, for which Astex will file, during the fourth quarter of 2007, an Investigational New Drug (IND) application with the FDA to start clinical trials; and

- AT9311, a selective, orally administered, inhibitor of CDKs, partnered with Novartis.

Astex also has five internal drug discovery programmes and is pursuing another six projects in partnership with leading pharmaceutical companies including Novartis, AstraZeneca, Bayer Schering and Boehringer Ingelheim.

Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Poster Title: A comparison of the pharmacological profile of AT7519 in solid tumor and hematological cell lines.

--------------------------------------------------------------------

Session Date : Tuesday, October 23, 2007, 12:30 PM

Session Title : Poster Session A

Session Subtitle : Small Molecule Therapeutic Agents: Kinase

Inhibitors

Session Time : 12:30-2:30 PM and 5:30-7:30 PM

Session Location : Exhibit Hall, First Floor, Moscone Convention

Center West

Abstract Number : A247

--------------------------------------------------------------------

Poster Title: AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation.

--------------------------------------------------------------------

Session Date : Wednesday, October 24, 2007, 12:30 PM

Session Title : Poster Session B

Session Subtitle : Small Molecule Therapeutic Agents: Kinase

Inhibitors

Session Time : 12:30-2:30 PM and 5:30-7:30 PM

Session Location : Exhibit Hall, First Floor, Moscone Convention

Center West

Abstract Number : B251

--------------------------------------------------------------------

About Astex

Astex Therapeutics is a biotechnology company that discovers and develops novel small molecule therapeutics. Using its pioneering fragment-based drug discovery platform Pyramid(TM), Astex has built a pipeline of five molecularly-targeted oncology drugs, of which two are currently being tested in clinical trials and three are in pre-clinical development.

In addition to its proprietary research programmes, Astex's unprecedented productivity in lead discovery has been endorsed through numerous partnerships with major pharmaceutical companies, including Novartis, AstraZeneca, and Boehringer Ingelheim.

For further information on Astex Therapeutics please visit the Company's website at http://www.astex-therapeutics.com

Web: http://www.astex-therapeutics.com


'/>"/>
SOURCE Astex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. What citizens dont ask political candidates
2. Candidates sparring over jobs focuses debate on right issue
3. To find solid security candidates, look beyond tech certificates
4. Presidential candidates stretch necks and facts
5. Innovation featured in NE Wisconsin Roundtable
6. Madison music featured on Internet radio station
7. Wisconsin biotech sector featured in scientific magazine
8. The Information Age of Healthcare - Leaders featured on local new economy show
9. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
10. Olympics of biotechnology has international flavor
11. Traffic data firm navigates international business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ReportsnReports.com adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):